CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals. The financial performance shows a slight improvement in net loss per share, and cash reserves are healthy. However, guidance was cut on the higher end, and sales force productivity is not fully realized. The Q&A reveals cautious optimism, with potential growth in 2026 but conservative Q4 guidance. There are positive developments in gross margin and reimbursement, but uncertainties in productivity improvements and market expansion remain. Without a market cap, the overall sentiment is neutral, expecting minimal stock movement.
Key Financial Performance
Revenue Revenue was $14.7 million for the 3 months ended September 30, 2025, an increase of $1.3 million or 10% over the 3 months ended September 30, 2024. The increase was primarily driven by continued growth in the U.S. heart failure business as a result of the expansion into new sales territories, new accounts, and increased physician and patient awareness of Barostim.
Revenue in the U.S. Revenue generated in the U.S. was $13.5 million for the 3 months ended September 30, 2025, an increase of $1.2 million or 10% over the 3 months ended September 30, 2024. The increase was driven by the same factors as overall revenue growth.
Revenue in Europe Revenue generated in Europe was $1.2 million for the 3 months ended September 30, 2025, an increase of $0.1 million or 12% over the 3 months ended September 30, 2024. However, total revenue units in Europe decreased to 50 from 56 in the prior year period.
Gross Profit Gross profit was $12.8 million for the 3 months ended September 30, 2025, an increase of $1.5 million or 15% over the 3 months ended September 30, 2024. Gross margin increased to 87% from 83% in the prior year period, driven by an increase in the average selling price and a decrease in the cost per unit due to improved manufacturing efficiencies.
R&D Expenses R&D expenses increased $0.6 million or 26% to $3.1 million for the 3 months ended September 30, 2025, compared to the prior year period. This was driven by a $0.5 million increase in compensation expenses and a $0.2 million increase in consulting expenses, partially offset by a $0.2 million decrease in clinical trial expenses.
SG&A Expenses SG&A expenses increased $0.2 million or 1% to $21.9 million for the 3 months ended September 30, 2025, compared to the prior year period. This was primarily driven by increases in consulting, travel, and non-cash stock-based compensation expenses, partially offset by decreases in advertising and compensation expenses.
Interest Expense Interest expense increased $0.5 million for the 3 months ended September 30, 2025, compared to the prior year period. This was driven by higher levels of borrowings under the term loan agreement with Innovatus Capital Partners.
Net Loss Net loss was $12.9 million or $0.49 per share for the 3 months ended September 30, 2025, compared to a net loss of $13.1 million or $0.57 per share for the prior year period. The improvement in net loss per share was due to an increase in weighted average shares outstanding.
Cash and Cash Equivalents As of September 30, 2025, cash and cash equivalents were $85.1 million. Net cash used in operating and investing activities was $10 million for the 3 months ended September 30, 2025, compared to $10.4 million for the prior year period.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Barostim therapy: The company is focusing on improving patient access, expanding therapy awareness, and building clinical evidence. CMS proposed maintaining Barostim in new technology APC 1580 with payment of approximately $45,000 for outpatient procedures. Transition to a Category I CPT code effective January 1, 2026, will improve prior authorization predictability and ensure fair physician payment.
U.S. market expansion: Revenue in the U.S. increased by 10% year-over-year to $13.5 million, driven by new sales territories, accounts, and increased awareness of Barostim. The number of active implanting centers grew to 250, and sales territories increased to 50.
European market: Revenue increased by 12% year-over-year to $1.2 million, though total revenue units decreased from 56 to 50. Sales territories remained consistent at 5.
Sales force transformation: The company is building a world-class sales organization, with turnover returning to normal levels. New sales reps are being onboarded and contributing meaningfully. The number of sales reps contributing implants reached a record high in Q3.
Manufacturing efficiencies: Gross margin increased to 87% from 83% year-over-year due to higher average selling prices and reduced cost per unit.
Strategic account targeting: The company is focusing on high-potential Tier 1 and Tier 2 accounts while selectively pursuing Tier 3 and Tier 4 accounts with committed physician champions and administrative support.
Clinical evidence and FDA discussions: The company is expanding its clinical evidence portfolio with positive patient outcomes reported. Discussions with the FDA for a new randomized controlled trial are progressing, with an IDE application submitted in October.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Sales Force Turnover: Although turnover is returning to normal levels, the company has faced challenges in maintaining a stable sales force, which could impact the consistency of sales efforts and customer relationships.
Territory Expansion: The company is expanding its sales territories, but this requires careful alignment of hiring and onboarding processes to ensure new hires are productive, which could delay revenue growth if not managed effectively.
Reimbursement Challenges: While progress has been made in reimbursement policies, the transition to a Category I CPT code and securing Category B IDE coverage are still pending, which could delay broader adoption of Barostim therapy.
Regulatory Uncertainty: Discussions with the FDA regarding a new randomized controlled trial are ongoing, and any delays or disagreements could impact the company's ability to generate new clinical evidence and secure necessary approvals.
Financial Losses: The company reported a net loss of $12.9 million for Q3 2025, indicating ongoing financial challenges that could limit its ability to invest in growth initiatives.
Interest Expense: Increased interest expenses due to higher borrowings could strain financial resources and impact profitability.
European Market Performance: Revenue units in Europe decreased, which could indicate challenges in market penetration or competition in that region.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Full-Year 2025: The company expects total revenue between $55.6 million and $56.6 million, compared to prior guidance of $55 million to $57 million.
Gross Margin Guidance for Full-Year 2025: The company now expects full-year gross margin between 85% and 86%, compared to prior guidance of 83% to 84%.
Operating Expenses Guidance for Full-Year 2025: The company now expects operating expenses between $98 million and $99 million, compared to prior guidance of $96 million to $98 million.
Revenue Guidance for Q4 2025: The company expects to report total revenue between $15 million and $16 million.
Transition to Category I CPT Code: Effective January 1, 2026, the company will transition to a Category I CPT code, which will eliminate experimental and investigational denials, improve prior authorization predictability, and ensure fair and consistent physician payment for procedures.
FDA IDE Application and Potential New Trial: The company submitted an IDE application in mid-October 2025 and expects feedback from the FDA in late November 2025. If approved, the company plans to approach CMS for Category B IDE coverage to move forward with a new randomized controlled trial.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why did the company cut the higher end of its guidance range despite positive productivity trends?
A:The company was pleased with Q3 results and saw continued performance into October, which led to raising the midpoint of the guidance. However, they acknowledged that work remains to be done in improving productivity and did not want to get ahead of themselves.
Q:Is the company comfortable with the Street's projection of 18.5% growth in 2026?
A:The company is targeting mid-teens growth in 2026, with potential acceleration in 2027 and beyond to mid-20% growth rates. They are still investing in sales reps, territories, and the business overall.
Q:What is the progress on sales force productivity improvements?
A:The company is pleased with the progress of new sales reps hired in the last three quarters. While many are active and contributing, full productivity is not yet achieved. It typically takes 6-12 months for new hires to fully contribute.
Q:What are the implications of the finalized Category I code in the physician fee schedule starting January 1?
A:The Category I code eliminates automatic denials of prior authorizations as experimental, requiring human clinician review and justification for denials. This is expected to reduce friction in the system, improve approval rates, and shorten approval times over time.
Q:What drove the better-than-expected gross margin in the quarter?
A:The improvement was due to a mix of increased average selling prices (ASPs) and reduced cost per unit. ASPs rose to over $31,000 globally, and manufacturing efficiencies in the Minneapolis facility reduced labor and overhead costs.
Q:Will the developments in reimbursement and sales force improvements drive sales growth acceleration in 2026?
A:The company expects mid-teens growth in 2026, with potential upside if factors like the Category I code, payer approvals, and sales force productivity align favorably.
Q:How is the company ensuring new sales reps get up to speed faster?
A:The company focuses on hiring individuals with program and market development skills, investing in sales training resources, and implementing a systematized training process. They also prioritize selecting the right accounts for faster ramp-up.
Q:What is the status and goal of the randomized controlled trial (RCT)?
A:The RCT aims to expand the target patient population by adjusting ejection fraction and NT-proBNP cutoffs, potentially tripling the total addressable market (TAM). The trial will involve around 2,000 patients and 100+ centers, with enrollment expected to start in the first half of 2026.
Q:What are the expectations for sales force growth in 2026?
A:The company plans to add approximately three new sales territories per quarter in 2026, with potential for increased hiring in the future.
Q:Why does Q4 guidance imply flat year-over-year growth despite improving sales force productivity?
A:The company is seeing sequential growth but remains cautious in its guidance as they work through the sales force transformation. They expect $1 million sequential growth from Q3 to Q4.
Q:What is the current state of sales force turnover and tenure?
A:Turnover has returned to normal levels (10-20% annually), and the company is back to normal hiring levels without significant changes in the percentage of reps hired in 2024 and 2025.
Q:What is the company's outlook on operating expenses (OpEx) for 2026?
A:The company expects OpEx growth to be lower than top-line growth, with leverage in the model as margins improve.
Q:Are there structural differences between top accounts averaging 3 implants versus those averaging 10?
A:There are no structural differences. The company believes all accounts can reach higher levels of adoption with the right tools, stakeholder engagement, and administrative support.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing whether there was conservatism in the Q4 guidance despite improving sales force productivity. They also did not provide specific details on the potential upside from the Level 6 neurostimulator code in the OPPS final rule.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APC payment
APPs heart
Barostim standard
Barostim therapy
CPT code
CVRx Conference
Category
Europe month
FDA
IDE
Medicare
Officer Hykes
Tier account
access
approach account
awareness Barostim
champion support
conference
contribution
day
failure patient
implanting center
increase consulting
increase month
margin month
month change
month margin
month unit
number sale
physician champion
portfolio
priority
registration statement
sale rep
standard care
therapy adoption
transformation
CVRX Transcript
CVRx, Inc. (CVRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
Positive5-11
The earnings call highlights a 22% revenue growth in the U.S., exceeding expectations, and positive impacts from 2025 investments, indicating strong performance. However, the absence of shareholder return discussions and risks associated with forward-looking statements introduce some uncertainty. Overall, the positive growth and strategic investments outweigh the risks, suggesting a positive stock price reaction.
CVRx, Inc. (CVRX) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call highlights several positive factors: improved revenue and gross margin guidance, the transition to a Category I CPT code, and strong confidence in future growth driven by sales rep productivity and center adoption. The Q&A section supports these positives, with management addressing concerns and outlining strategic initiatives. Despite some vague responses, the overall sentiment is optimistic, with potential catalysts like the FDA IDE application and the BENEFIT trial. The market is likely to react positively, predicting a 2% to 8% increase in stock price.
CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
CVRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
